At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VIR Vir Biotechnology, Inc.
Post-Mkt 10-26 17:24:23 EDT
11.04
+0.47
+4.45%
盘后10.98
-0.06-0.54%
16:23 EDT
High11.10Low10.60Vol1.59M
Open10.64D1 Closing10.57Amplitude4.68%
Mkt Cap1.86BTradable Cap1.44BTotal Shares168.65M
T/O17.35MT/O Rate1.22%Tradable Shares130.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Spero Therapeutics Names Amy Rock Chief Regulatory and Quality Officer
Reuters  ·  10-26 20:08
Spero Therapeutics Names Amy Rock Chief Regulatory and Quality Officer
A 42% Risk Reduction—and an 18% Stock Drop
Bellwether Stocks Movement  ·  10-24 22:29
A 42% Risk Reduction—and an 18% Stock Drop
Vir Biotechnology to Host Third-Quarter Financial Results Call
Reuters  ·  10-22
Vir Biotechnology to Host Third-Quarter Financial Results Call
Gilead Cancer Drug Deal Might Change The Case For Investing In Vir Biotechnology (VIR)
Simply Wall St.  ·  10-20
Gilead Cancer Drug Deal Might Change The Case For Investing In Vir Biotechnology (VIR)
One Failed Endpoint Just Erased Most of EyePoint’s Value
Bellwether Stocks Movement  ·  10-20
One Failed Endpoint Just Erased Most of EyePoint’s Value
Analysts’ Top Healthcare Picks: Eli Lilly & Co (LLY), Vir Biotechnology (VIR)
TIPRANKS  ·  10-19
Analysts’ Top Healthcare Picks: Eli Lilly & Co (LLY), Vir Biotechnology (VIR)
Vir Biotechnology (VIR) Could Be 54% Undervalued After Gilead Collaboration
Simply Wall St.  ·  10-18
Vir Biotechnology (VIR) Could Be 54% Undervalued After Gilead Collaboration
Novartis’ Pipeline Is Cracking—And The Stock Isn’t
Bellwether Stocks Movement  ·  10-17
Novartis’ Pipeline Is Cracking—And The Stock Isn’t
From Algorithms To Oncology: Why IAM Jumped On Day One
Bellwether Stocks Movement  ·  10-16
From Algorithms To Oncology: Why IAM Jumped On Day One
Inflation Shock Sends Wall Street Lower—Why Big Pharma Became The Market’s Refuge
Sector Pulse  ·  10-16
Inflation Shock Sends Wall Street Lower—Why Big Pharma Became The Market’s Refuge
Pharma Stocks Jump. Eli Lilly, AstraZeneca up over 4%; Novo Nordisk up over 3%; Moderna, J&J, Merck, Pfizer up over 2%
Tiger Newspress  ·  10-15
Pharma Stocks Jump. Eli Lilly, AstraZeneca up over 4%; Novo Nordisk up over 3%; Moderna, J&J, Merck, Pfizer up over 2%
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  10-14
Wall Street Analysts Are Bullish on Top Healthcare Picks
Vir Biotechnology Shares Jump on Gilead Cancer Collaboration
Dow Jones  ·  10-14
Vir Biotechnology Shares Jump on Gilead Cancer Collaboration
Vir Biotechnology Shares Rise 1.7% on up to $1.9 Bln Licensing Deal with Gilead
THOMSON REUTERS  ·  10-14
Vir Biotechnology Shares Rise 1.7% on up to $1.9 Bln Licensing Deal with Gilead
Vir Biotechnology Gains After up to $1.9 Billion Licensing Deal with Gilead
Reuters  ·  10-14
Vir Biotechnology Gains After up to $1.9 Billion Licensing Deal with Gilead
Vir Biotechnology Shares Rise 11.3% Premarket on Partnership with Gilead Sciences
THOMSON REUTERS  ·  10-14
Vir Biotechnology Shares Rise 11.3% Premarket on Partnership with Gilead Sciences
Vir Biotechnology enters collaboration, license agreement with Gilead
TIPRANKS  ·  10-14
Vir Biotechnology enters collaboration, license agreement with Gilead
Vir Biotechnology - Gilead to Purchase 1,765,486 Vir Bio Shares at $14.16 Per Share for $25 Mln - SEC Filing
THOMSON REUTERS  ·  10-14
Vir Biotechnology - Gilead to Purchase 1,765,486 Vir Bio Shares at $14.16 Per Share for $25 Mln - SEC Filing
Vir Biotechnology Partners with Gilead to Develop PRO-XTEN Dual-Masked T-Cell Engagers for Solid Tumors
Reuters  ·  10-14
Vir Biotechnology Partners with Gilead to Develop PRO-XTEN Dual-Masked T-Cell Engagers for Solid Tumors
Vir Biotechnology - Eligible for up to $135 Mln in Upfront and Preclinical Milestones
THOMSON REUTERS  ·  10-14
Vir Biotechnology - Eligible for up to $135 Mln in Upfront and Preclinical Milestones

Introduction

Company Name.
Vir Biotechnology, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Issue price:
--